

2019 Future of Hepatic Encephalopathy (HE) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2F218EF774EEN.html>

Date: February 2019

Pages: 45

Price: US\$ 2,199.00 (Single User License)

ID: 2F218EF774EEN

Abstracts

The global demand for Hepatic Encephalopathy (HE) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Hepatic Encephalopathy (HE) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Hepatic Encephalopathy (HE) pipeline companies from advancing their products into Phase 3 or Phase 4.

Hepatic Encephalopathy (HE) Report Description-

The 2019 pipeline study on Hepatic Encephalopathy (HE) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Hepatic Encephalopathy (HE) pipeline compounds.

The Hepatic Encephalopathy (HE) pipeline guide presents information on all active drugs currently being developed for Hepatic Encephalopathy (HE). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Hepatic Encephalopathy (HE) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Hepatic Encephalopathy (HE) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Hepatic Encephalopathy (HE) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Hepatic Encephalopathy (HE) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Hepatic Encephalopathy (HE) pipeline report includes-

An overview of Hepatic Encephalopathy (HE) disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Hepatic Encephalopathy (HE) pipeline

Company wise list of Hepatic Encephalopathy (HE) pipeline

Mechanism of Action wise Hepatic Encephalopathy (HE) pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Hepatic Encephalopathy (HE) pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Hepatic Encephalopathy (HE) pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Hepatic Encephalopathy (HE) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL HEPATIC ENCEPHALOPATHY (HE) PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Hepatic Encephalopathy (HE) Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Hepatic Encephalopathy (HE) pipeline, H1- 2019
- 3.5 Mechanism of Action wise Hepatic Encephalopathy (HE) Pipeline Candidates

4 ALFASIGMA SPA HEPATIC ENCEPHALOPATHY (HE) PIPELINE DETAILS

- 4.1 AlfaSigma SpA Business Profile
- 4.2 AlfaSigma SpA Hepatic Encephalopathy (HE) Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 COSMO PHARMACEUTICALS NV HEPATIC ENCEPHALOPATHY (HE) PIPELINE DETAILS

- 5.1 Cosmo Pharmaceuticals NV Business Profile
- 5.2 Cosmo Pharmaceuticals NV Hepatic Encephalopathy (HE) Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 FERRING INTERNATIONAL CENTER SA HEPATIC ENCEPHALOPATHY (HE) PIPELINE DETAILS

- 6.1 Ferring International Center SA Business Profile
- 6.2 Ferring International Center SA Hepatic Encephalopathy (HE) Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details

6.7 Latest Drug Developments

7 GILEAD SCIENCES INC HEPATIC ENCEPHALOPATHY (HE) PIPELINE DETAILS

7.1 Gilead Sciences Inc Business Profile

7.2 Gilead Sciences Inc Hepatic Encephalopathy (HE) Drug Details

7.3 Drug Snapshot

7.3.1 Originator

7.3.2 Collaborator/Co-Developer

7.3.3 Route of Administration

7.3.4 Orphan Drug/Fast Track/Special Designation

7.3.5 Geography

7.3.6 Type of Molecular Entity

7.3.7 Current Status

7.4 Drug Overview

7.5 Drug Mechanism of Action

7.6 Clinical/Pre-clinical Trial Details

7.7 Latest Drug Developments

8 KANNALIFE SCIENCES INC HEPATIC ENCEPHALOPATHY (HE) PIPELINE DETAILS

8.1 KannaLife Sciences Inc Business Profile

8.2 KannaLife Sciences Inc Hepatic Encephalopathy (HE) Drug Details

8.3 Drug Snapshot

8.3.1 Originator

8.3.2 Collaborator/Co-Developer

8.3.3 Route of Administration

8.3.4 Orphan Drug/Fast Track/Special Designation

8.3.5 Geography

8.3.6 Type of Molecular Entity

8.3.7 Current Status

8.4 Drug Overview

8.5 Drug Mechanism of Action

8.6 Clinical/Pre-clinical Trial Details

8.7 Latest Drug Developments

9 MALLINCKRODT PLC HEPATIC ENCEPHALOPATHY (HE) PIPELINE DETAILS

- 9.1 Mallinckrodt Plc Business Profile
- 9.2 Mallinckrodt Plc Hepatic Encephalopathy (HE) Drug Details
- 9.3 Drug Snapshot
 - 9.3.1 Originator
 - 9.3.2 Collaborator/Co-Developer
 - 9.3.3 Route of Administration
 - 9.3.4 Orphan Drug/Fast Track/Special Designation
 - 9.3.5 Geography
 - 9.3.6 Type of Molecular Entity
 - 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 SPHERIUM BIOMED SL HEPATIC ENCEPHALOPATHY (HE) PIPELINE DETAILS

- 10.1 Spherium Biomed SL Business Profile
- 10.2 Spherium Biomed SL Hepatic Encephalopathy (HE) Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 SYNLOGIC INC HEPATIC ENCEPHALOPATHY (HE) PIPELINE DETAILS

- 11.1 Synlogic Inc Business Profile
- 11.2 Synlogic Inc Hepatic Encephalopathy (HE) Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer

- 11.3.3 Route of Administration
- 11.3.4 Orphan Drug/Fast Track/Special Designation
- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 UMECRINE COGNITION AB HEPATIC ENCEPHALOPATHY (HE) PIPELINE DETAILS

- 12.1 Umechrine Cognition AB Business Profile
- 12.2 Umechrine Cognition AB Hepatic Encephalopathy (HE) Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13. LATEST HEPATIC ENCEPHALOPATHY (HE) DRUG PIPELINE DEVELOPMENTS, 2019

14. APPENDIX

- 14.1 About Us
- 14.2 Sources and Methodology
- 14.3 Contact Information

I would like to order

Product name: 2019 Future of Hepatic Encephalopathy (HE) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2F218EF774EEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2F218EF774EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970